» Articles » PMID: 11792325

The Nucleoporin RanBP2 Has SUMO1 E3 Ligase Activity

Overview
Journal Cell
Publisher Cell Press
Specialty Cell Biology
Date 2002 Jan 17
PMID 11792325
Citations 345
Authors
Affiliations
Soon will be listed here.
Abstract

Posttranslational modification with SUMO1 regulates protein/protein interactions, localization, and stability. SUMOylation requires the E1 enzyme Aos1/Uba2 and the E2 enzyme Ubc9. A family of E3-like factors, PIAS proteins, was discovered recently. Here we show that the nucleoporin RanBP2/Nup358 also has SUMO1 E3-like activity. RanBP2 directly interacts with the E2 enzyme Ubc9 and strongly enhances SUMO1-transfer from Ubc9 to the SUMO1 target Sp100. The E3-like activity is contained within a 33 kDa domain of RanBP2 that lacks RING finger motifs and does not resemble PIAS family proteins. Our findings place SUMOylation at the cytoplasmic filaments of the NPC and suggest that, at least for some substrates, modification and nuclear import are linked events.

Citing Articles

SUMO2/3 conjugation of TDP-43 protects against aggregation.

Verde E, Antoniani F, Mediani L, Secco V, Crotti S, Ferrara M Sci Adv. 2025; 11(8):eadq2475.

PMID: 39982984 PMC: 11844728. DOI: 10.1126/sciadv.adq2475.


Structural basis for a nucleoporin exportin complex between RanBP2, SUMO1-RanGAP1, the E2 Ubc9, Crm1 and the Ran GTPase.

Baytshtok V, DiMattia M, Lima C bioRxiv. 2025; .

PMID: 39763778 PMC: 11703149. DOI: 10.1101/2024.10.04.616749.


SUMOylation of Warts kinase promotes neural stem cell reactivation.

Gao Y, Tan Y, Lin J, Chew L, Aung H, Palliyana B Nat Commun. 2024; 15(1):8557.

PMID: 39419973 PMC: 11487185. DOI: 10.1038/s41467-024-52569-y.


Advances in the understanding of nuclear pore complexes in human diseases.

Li Y, Zhu J, Zhai F, Kong L, Li H, Jin X J Cancer Res Clin Oncol. 2024; 150(7):374.

PMID: 39080077 PMC: 11289042. DOI: 10.1007/s00432-024-05881-5.


Unlocking the Gateway: The Spatio-Temporal Dynamics of the p53 Family Driven by the Nuclear Pores and Its Implication for the Therapeutic Approach in Cancer.

Ikliptikawati D, Makiyama K, Hazawa M, Wong R Int J Mol Sci. 2024; 25(13).

PMID: 39000572 PMC: 11242911. DOI: 10.3390/ijms25137465.